Company Filing History:
2 out of 1,274 
1 out of 444 
1 out of 504 
Years Active: 1985-2021
Title: Michael R Knowles: Innovator in Lung Disease Treatment
Introduction
Michael R Knowles is a prominent inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of lung disease treatment, holding a total of 3 patents. His work focuses on innovative methods to address conditions such as cystic fibrosis and chronic obstructive pulmonary disease.
Latest Patents
One of his latest patents involves the use of MTAP inhibitors for the treatment of lung disease. This invention relates to the application of 5'-methylthioadenosine phosphorylase (MTAP) inhibitors to treat lung diseases associated with inflammation. The use of small molecule inhibitors of MTAP can lead to the accumulation of endogenous MTA, which is beneficial in reducing inflammation in conditions like cystic fibrosis and COPD.
Another significant patent is the method of administering amiloride. This method outlines techniques for removing retained mucus secretions from the lungs of human subjects. It includes generating an aerosol suspension of respirable solid, dry particulate amiloride and delivering it through inhalation to the respiratory system. The treatment aims to hydrate secretions, making them easier to transport from the lungs via mucociliary action.
Career Highlights
Michael R Knowles has worked with notable institutions, including the University of North Carolina at Chapel Hill and Research, Incorporated. His career has been marked by a commitment to advancing medical treatments for respiratory diseases.
Collaborations
Throughout his career, Knowles has collaborated with esteemed colleagues such as Richard C Boucher and John T Gatzy. These partnerships have contributed to the development of innovative solutions in lung disease treatment.
Conclusion
Michael R Knowles is a dedicated inventor whose work has the potential to significantly improve the lives of individuals suffering from lung diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.